Senores Pharms receives AP status for Pravastatin Sodium ANDA077491
Senores Pharmaceuticals has received Abbreviated Approval (AP) from the FDA for their ANDA077491 application for Pravastatin Sodium, a statin indicated for cholesterol management.
Company
Pharmaceutical intelligence for Senores Pharmaceuticals with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.